FB23‐2 significantly affects the proliferation, differentiation, and apoptosis of human acute myeloid leukemia cells in vitro and in vivo.[156] These results suggest that small‐molecule inhibitors specifically targeting FTO could be developed for fighting against obesity‐related metabolic disorders and other events (Figure 5). Here, FTO is linked to obesity disorder.